Eli Lilly and Taisho ended a licence agreement over experimental type 2 diabetes drug TS-021. Taisho noted Monday that the move comes after "pre-clinical study results did not meet certain criteria set by Lilly."
Lilly obtained the exclusive development and marketing rights to TS-021 from Taisho in July 2005 for all countries, excluding China and Japan. Taisho said it plans to continue developing the drug, which is now in Phase I trials, news sources report.
To read more Top Story articles, click here.